
Individuals ≥50 years of age without contraindications who received LZV, or who have had a previous episode of HZ, should be vaccinated with RZV after at least one year.RZV is recommended for individuals ≥50 years of age without contraindications.Two different HZ vaccines are currently authorized for use in Canada: Zostavax II ® (Live Zoster Vaccine, LZV), and Shingrix ® (Recombinant Zoster Vaccine, RZV).HZ vaccines reduce the incidence of HZ and PHN.Post-herpetic neuralgia (PHN), which can be debilitating, is the most frequent complication of HZ.HZ is characterized by neuropathic pain and dermatomal vesicular rash.Herpes zoster (HZ) occurs most frequently among older adults and immunocompromised persons.


Administration of the HZ vaccines: Table 1 was added to summarize key information.Recommendations for use in different populations.Most sections were revised to include information and practice recommendations for the new recombinant zoster vaccine (RZV) which is now available in Canada.

Last complete chapter revision: August 2018Īugust 2018 –This chapter was revised to reflect NACI's Updated Recommendations on the Use of Herpes Zoster Vaccines.
